EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Holmium-166 radioembolisation dosimetry in HCC

Margot T M Reinders iD, Arthur J A T Braat iD, Karel J van Erpecum iD, Joep de Bruijne, Rutger C G Bruijnen iD, Dave Sprengers iD, Rob de Man, Erik Vegt iD, Jan N M IJzermans iD, Sjoerd G Elias iD, Marnix G E H Lam iD, Maarten L J Smits iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-02 · 52 (3) · 993-1003

DOI: 10.1007/s00259-024-06940-2 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.10.2024. Verfasst von Margot T M Reinders und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Utrecht University - University Medical Centre Utrecht, P.O. Box 85500 100, 3500 GA, Utrecht, the Netherl…. Hauptthemen laut MEDLINE: Holmium, Liver Neoplasms, Carcinoma, Hepatocellular, Radioisotopes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate dosimetry, dose–response and dose-toxicity relationships for holmium-166 ( 166 Ho) radioembolisation in patients with hepatocellular carcinoma (HCC).

Methods

Thirty-one patients with hepatocellular carcinoma were included in the HEPAR Primary study (NCT03379844, registered on December 20th, 2017) and underwent 166 Ho-microspheres radioembolisation. Linear mixed models assessed the association between tumour absorbed doses and response based on mRECIST both on tumour and patient level. Preliminary tumour absorbed dose thresholds were estimated based on predictive value. Linear regression models assessed the association between non-tumour absorbed dose and Common Terminology Criteria for Adverse Events version 4.03.

Results

Median tumour absorbed dose (tumour level) was 95.5 Gy (range 44—332 Gy). Median non-tumour absorbed dose based on whole liver volume was 19 Gy (range 3 – 48 Gy) and based on target liver volume was 30 Gy (range 13 – 54 Gy). There was a significant association between non-tumour absorbed dose and toxicity. Tumours with partial response/complete response (PR/CR, responders) received a 41% higher absorbed dose than tumours with progressive disease/stable disease (PD/SD, non-responders) (95%CI: 2%-93%, p = 0.04). A predictive value of 90% for tumour response was observed at a tumour absorbed dose threshold of 155 Gy, 100% predictive value was achieved at 184.5 Gy.

Conclusion

This study confirms a positive relationship between tumour absorbed dose and response and between non-tumour absorbed dose and toxicity. Dose thresholds found in this study can serve as a basis for personalized dosimetry in HCC patients treated with 166 Ho-microspheres.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HolmiumLiver NeoplasmsCarcinoma, HepatocellularRadioisotopesEmbolization, TherapeuticHumansMaleFemaleMiddle AgedAgedRadiometryRadiotherapy DosageAdultAged, 80 and over

Stichwörter der Autor:innen

BiodistributionDosimetryHepatocellular carcinomaHolmiumPersonalised treatment planningRadioembolisation

Substanzen

HolmiumHolmium-166Radioisotopes

Autor:innen und Institutionen

  • Department of Radiology & Nuclear Medicine, Utrecht University - University Medical Centre Utrecht, P.O. Box 85500 100, 3500 GA, Utrecht, the Netherlands.
  • Department of Gastroenterology & Hepatology, Utrecht University - University Medical Centre Utrecht, P.O. Box 85500 100, 3500 GA, Utrecht, the Netherlands.
  • Department of Gastroenterology & Hepatology, Erasmus MC-University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
  • Department of Radiology & Nuclear Medicine, Erasmus MC-University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
  • Department of Surgery, Erasmus MC-University Medical Centre Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
  • Julius Centre for Health Sciences and Primary Care, Utrecht University - University Medical Centre Utrecht, P.O. Box 85500 100, 3500 GA, Utrecht, the Netherlands.

ORCID-Profile: Margot T M Reinders, Arthur J A T Braat, Karel J van Erpecum, Rutger C G Bruijnen, Dave Sprengers, Erik Vegt, Jan N M IJzermans, Sjoerd G Elias, Marnix G E H Lam, Maarten L J Smits

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Reinders, M. T. M., Braat, A. J. A. T., van Erpecum, K. J., de Bruijne, J., Bruijnen, R. C. G., Sprengers, D., de Man, R., Vegt, E., IJzermans, J. N. M., Elias, S. G., Lam, M. G. E. H., & Smits, M. L. J. (2025). Holmium-166 radioembolisation dosimetry in HCC. European Journal of Nuclear Medicine and Molecular Imaging, 52(3), 993-1003. https://doi.org/10.1007/s00259-024-06940-2

Vancouver

Reinders MTM, Braat AJAT, van Erpecum KJ, de Bruijne J, Bruijnen RCG, Sprengers D, et al. Holmium-166 radioembolisation dosimetry in HCC. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(3):993-1003. doi:10.1007/s00259-024-06940-2

BibTeX
@article{Reinders2025,
  author = {Reinders, Margot T M and Braat, Arthur J A T and van Erpecum, Karel J and de Bruijne, Joep and Bruijnen, Rutger C G and Sprengers, Dave and de Man, Rob and Vegt, Erik and IJzermans, Jan N M and Elias, Sjoerd G and Lam, Marnix G E H and Smits, Maarten L J},
  title = {Holmium-166 radioembolisation dosimetry in HCC},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {3},
  pages = {993--1003},
  doi = {10.1007/s00259-024-06940-2}
}
Kostenlos starten →